Diabetes and coronary artery disease: The role of stress myocardial perfusion imaging

Frans J. TH. Wackers, MD
Professor of Diagnostic Radiology and Medicine; Director, Cardiovascular Nuclear Imaging and Exercise Laboratories; Yale University School of Medicine, New Haven, CT

Address: Frans J. Th. Wackers, MD, Director, Cardiovascular Nuclear Imaging and Exercise Laboratories, Yale University School of Medicine, 333 Cedar Street, FMP 3, PO Box 208042, New Haven, CT 06520-8042; e-mail frans.wackers@yale.edu

The author has indicated that he is on the speakers’ bureaus of Amersham and Bristol-Myers Squibb Medical Imaging, is a consultant for King Pharmaceuticals, and has received grant or research support from Bristol-Myers Squibb Medical Imaging and Fujisawa.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Frans J. TH. Wackers, MD
Professor of Diagnostic Radiology and Medicine; Director, Cardiovascular Nuclear Imaging and Exercise Laboratories; Yale University School of Medicine, New Haven, CT

Address: Frans J. Th. Wackers, MD, Director, Cardiovascular Nuclear Imaging and Exercise Laboratories, Yale University School of Medicine, 333 Cedar Street, FMP 3, PO Box 208042, New Haven, CT 06520-8042; e-mail frans.wackers@yale.edu

The author has indicated that he is on the speakers’ bureaus of Amersham and Bristol-Myers Squibb Medical Imaging, is a consultant for King Pharmaceuticals, and has received grant or research support from Bristol-Myers Squibb Medical Imaging and Fujisawa.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Frans J. TH. Wackers, MD
Professor of Diagnostic Radiology and Medicine; Director, Cardiovascular Nuclear Imaging and Exercise Laboratories; Yale University School of Medicine, New Haven, CT

Address: Frans J. Th. Wackers, MD, Director, Cardiovascular Nuclear Imaging and Exercise Laboratories, Yale University School of Medicine, 333 Cedar Street, FMP 3, PO Box 208042, New Haven, CT 06520-8042; e-mail frans.wackers@yale.edu

The author has indicated that he is on the speakers’ bureaus of Amersham and Bristol-Myers Squibb Medical Imaging, is a consultant for King Pharmaceuticals, and has received grant or research support from Bristol-Myers Squibb Medical Imaging and Fujisawa.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.